<html>
<head>PUBMED IDs for FLJ10540</head>
<body bgcolor='#C5F0F2'><h1>FLJ10540</h1><a href='https://pubmed.ncbi.nlm.nih.gov/17237822/'>FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway.</a> January 24  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/19337377/'>VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.</a> June 13  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19525975/'>Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity.</a> August 12  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/20217555/'>Using siRNA to uncover novel oncogenic signaling pathways.</a> May 18  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/22591637/'>FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway.</a> November 1  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24386352/'>Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis.</a> September 1  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25889801/'>Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer.</a> January 15  2015<br></body></html>
